Camurus

Camurus is a Swedish, science-led commercial-stage biopharmaceutical company focused on long-acting medicines for severe and chronic diseases. The company markets Buvidal for opioid dependence in Europe, Australia and other regions, licenses the same product in North America as Brixadi through Braeburn, and launched Oczyesa for acromegaly in Europe. Its lead proprietary technology platform, FluidCrystal, enables long-acting injectable depots designed for convenient self-administration and sustained drug release over extended periods. Camurus is also advancing a late-stage pipeline led by CAM2029 across acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease, alongside earlier programs in pain, obesity, and endocrine disorders. The company operates internationally with headquarters in Lund, Sweden and is listed on Nasdaq Stockholm.